MedTrace Logo

Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

NCT05557695 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2026-04-23

No results posted yet for this study

Summary

This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.

Conditions

  • Chronic Lymphocytic Leukemia, CLL

Interventions

DRUG

Acalabrutinib

Acalabrutinib

Sponsors & Collaborators

  • UKCLL Forum

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Toby A Eyre · Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2027-04-01
Completion
2027-04-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05557695 on ClinicalTrials.gov